The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.
Altered glycosylation in cancer: A promising target for biomarkers and therapeutics
Open accessAbstract
Glycosylation is a well-regulated cell and microenvironment specific post-translational modification. Several glycosyltransferases and glycosidases orchestrate the addition of defined glycan structures on the proteins and lipids. Recent advances and systemic approaches in glycomics have significantly contributed to a better understanding of instrumental roles of glycans in health and diseases. Emerging research evidence recognized aberrantly glycosylated proteins as the modulators of the malignant phenotype of cancer cells. The Cancer Genome Atlas has identified alterations in the expressions of glycosylation-specific genes that are correlated with cancer progression. However, the mechanistic basis remains poorly explored. Recent researches have shown that specific changes in the glycan structures are associated with ‘stemness’ and epithelial-to-mesenchymal transition of cancer cells. Moreover, epigenetic changes in the glycosylation pattern make the tumor cells capable of escaping immunosurveillance mechanisms. The deciphering roles of glycans in cancer emphasize that glycans can serve as a source for the development of novel clinical biomarkers. The ability of glycans in intervening various stages of tumor progression and the biosynthetic pathways involved in glycan structures constitute a promising target for cancer therapy. Advances in the knowledge of innovative strategies for identifying the mechanisms of glycan-binding proteins are hoped to hold great potential in cancer therapy. This review discusses the fundamental role of glycans in regulating tumorigenesis and tumor progression and provides insights into the influence of glycans in the current tactics of targeted therapies in the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–222 of 222
A predictive model for prostate cancer incorporating PSA molecular forms and age
Oto, J., Fernández‐Pardo, Á., Royo, M., Hervás, D., Martos, L., Vera-Donoso, C. D., Martínez, M., Heeb, M. J., España, F., Medina, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58836-4 · Cited by 33
Ishikawa, M., Kitayama, J., Nariko, H., et al. (2004) · Journal of Surgical Oncology · doi:10.1002/jso.20042 · Cited by 32
Aberrant glycosylation of αvβ3 integrin is associated with melanoma progression.
Pocheć, E., Bubka, M., Rydlewska, M., et al. (2015) · PubMed · Cited by 31
GALNT11 as a new molecular marker in chronic lymphocytic leukemia
Libisch, G., Casás, M., Chiribao, M., Moreno, P., Cayota, A., Osinaga, E., Oppezzo, P., & Robello, C. (2013) · Gene · doi:10.1016/j.gene.2013.09.052 · Cited by 30
SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line
Grover, P., Nath, S., Nye, M. D., Zhou, R., Ahmad, M., & Mukherjee, P. (2018) · Oncotarget · doi:10.18632/oncotarget.23966 · Cited by 29
Downregulation of the GnT-V gene inhibits metastasis and invasion of BGC823 gastric cancer cells
HUANG, B., Sun, L., Cao, J., ZHANG, Y., Wu, Q., Zhang, J., GE, Y., Fu, L., & Wang, Z. (2013) · Oncology Reports · doi:10.3892/or.2013.2373 · Cited by 28
Khanh, D. T., Mekata, E., Mukaisho, K., Sugihara, H., Shimizu, T., Shiomi, H., Murata, S., Naka, S., Yamamoto, H., Endo, Y., et al. (2013) · Cancer Science · doi:10.1111/cas.12170 · Cited by 28
Liu, D., Gao, Z., & Yue, L. (2019) · Cancer Biomarkers · doi:10.3233/cbm-190209 · Cited by 28
Xu, D., Wang, W., Bian, T., Yang, W., Shao, M., & Yang, H. (2019) · Europe PMC (PubMed Central) · Cited by 28
Pakkiriswami, S., Couto, A., Nagarajan, U., & Γεωργίου, Μ. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00037 · Cited by 27
Merlotti, A., Malizia, Á. L., Michea, P., Bonté, P., Goudot, C., Carregal, M. S., Núñez, N. G., Sedlik, C., Ceballos, A., Soumelis, V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629257 · Cited by 27
Glycoconjugates As Vaccines for Cancer Immunotherapy: Clinical Trials and Future Directions
Franco, A. (2008) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152008783330888 · Cited by 24
Larrain, M. I., Demichelis, S. O., Crespo, M., Lacunza, E., Barbera, A., Cretón, A., Terrier, F., Segal‐Eiras, A., & Croce, M. V. (2009) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-28-121 · Cited by 24
Soni, K. S., Thomas, D., Caffrey, T. C., Mehla, K., Lei, F., O’Connell, K. A., Sagar, S., Lele, S. M., Hollingsworth, M. A., Radhakrishnan, P., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255372 · Cited by 23
Self-citationMonoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity
Chua, J. X., Vankemmelbeke, M. N., McIntosh, R. S., Clarke, P. A., Moss, R. S., Parsons, T., Spendlove, I., Zaitoun, A. M., Madhusudan, S., & Durrant, L. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3030 · Cited by 22
Review of Clinical Studies of CA 27.29 in Breast Cancer Management
Beveridge, R. A. (1999) · The International Journal of Biological Markers · doi:10.1177/172460089901400107 · Cited by 20
Semaan, S. M., Wang, X., Marshall, A. G., & Sang, Q. A. (2012) · Journal of Cancer · doi:10.7150/jca.4592 · Cited by 19
Sun, E., Ma, C., Lu, B., et al. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s107445 · Cited by 19
Yi, L., Hu, Q., Zhou, J., Liu, Z., & Li, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.01.064 · Cited by 17
Moi, S., Lee, Y., Chuang, L., Yuan, S. F., Ou‐Yang, F., Hou, M., Yang, C.-H., & Chang, H. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0517-z · Cited by 15
The Evolution of the Use of Serum Alpha-fetoprotein in Clinical Liver Cancer Surveillance
Kelly, S. L., & Bird, T. G. (2016) · Journal of Immunobiology · doi:10.4172/2476-1966.1000116 · Cited by 10
Hsing (1996) · doi:10.1002/(sici)1097-0215(19960208)65:4 · Cited by 1
Cited by
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Xu, X., Peng, Q., Jiang, X., Tan, S., Yang, Y., Yang, W., Han, Y., Chen, Y., Oyang, L., Lin, J., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01020-1 · Cited by 276
Glycosylation in cancer: mechanisms, diagnostic markers, and therapeutic applications
Qusairy, Z., & Rada, M. (2025) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05303-1 · Cited by 16
Unraveling the glycosylated immunopeptidome with HLA-Glyco
Bedran, G., Polasky, D. A., Hsiao, Y., Yu, F., da Veiga Leprevost, F., Alfaro, J. A., Cieslik, M., & Nesvizhskii, A. I. (2023) · Nature Communications · doi:10.1038/s41467-023-39270-2 · Cited by 15
Yingli, H., Ping, Y., Jun, Y., & Xingwang, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167853 · Cited by 7
Metadata
- Authors
- Thomas, D., Rathinavel, A. K., & Radhakrishnan, P.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 1875
- Issue
- 1
- Pages
- 188464
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3097586971
- Cited by
- 372
- References
- 222
- FWCI
- 8.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.